Reply to Roesler et al. concerning the MEVITEM trial

Neuro Oncol. 2022 Jul 1;24(7):1212. doi: 10.1093/neuonc/noac084.

Authors

Didier Frappaz¹, Marc Barritault²

Affiliations

¹ Neuro-Oncology Unit, Centre Léon Bérard, Lyon, France.
² Neuropathology Department, CHRU de Lyon, Lyon, France.

No abstract available

Publication types

Comment